CD274 and gastric cancer: The KEYNOTE-059 clinical trial developed by Fuchs et al. also indicated that Pembrolizumab, a PD-1 inhibitor, indicated a relatively high response rate and lasting response to PD-L1 positive patients with advanced GC [13].